Trial Profile
A phase II study of bevacizumab in combination with metronomic temozolomide for recurrent malignant glioma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 May 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Temozolomide (Primary)
- Indications Glioma
- Focus Therapeutic Use
- 22 Jan 2009 Additional lead trial centres identified as reported by ClinicalTrials.gov, last updated 22 Jan 2009.
- 22 Jan 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 22 Jan 2009 Planned end date changed to 1 Oct 2009 as reported by ClinicalTrials.gov.